Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5562 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA 2018-12-05
Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA 2018-12-05
CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG 2018-12-05
Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG 2018-12-05
Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH 2018-12-05
Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH 2018-12-05
Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH 2018-12-05
Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH 2018-12-05
Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est 2018-12-04
Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF 2018-12-04
Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est 2018-12-04
Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs 2018-12-04
Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets 2018-12-04
Argenx–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC 2018-12-03
JnJ–Argenx: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
Hookipa–DarwinHealth: personalised medicine, 201811– collab research + license agreem to develop I-O treatments using systems biology 2018-11-28
Jecure Therapeutics–Roche: investment, 201811 acquisition of Jecure by Genentech from Versant Ventures 2018-11-27
Spindiag–SEVERAL: investment, 201811 financing round Series A €3m 2018-11-27
X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED 2018-11-27
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Adrenomed–MC Services: public relations, 201811 service existent by MC Services 2018-11-26
Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors 2018-11-26
Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners 2018-11-26
Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development 2018-11-26
Suntory–BRAIN: food ingredients, 201811– collab €na developm natural beverage solutions with SBFE 2018-11-26
F2G Ltd–EU (govt): credit, 201811– InnovFin €24m loan from EIB to F2G Biotech GmbH for antifungals r+d 2018-11-22
Evotec–Immuneering: drug discovery software, 201811– collab AI-driven small-molecule drug discovery for hereditary metabolic diseases 2018-11-21
Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen 2018-11-20
Inflazome–Forbion: investment, 201811 financing round Series B totalling €40m incl new + lead investor Forbion Capital Partners 2018-11-19
Inflazome–Fountain Healthcare Partners: investment, 201811 financing round Series B totalling €40m incl existing + co-investor FHP 2018-11-19
Inflazome–Longitude Capital: investment, 201811 financing round Series B totalling €40m incl new + co-investor Longitude Capital 2018-11-19
Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund 2018-11-19
Inflazome–SEVERAL: investment, 201811 financing round Series B €40m from Forbion + Longitude Capital + NVF + Fountain Healthcare Partners 2018-11-19
Lonza–Chaim Sheba Medical Center: cell therapy manufacturing technology, 201811 collab existent to evaluate + test Cocoon technology 2018-11-19
Roche–Immunocore: ImmTAC technology, 201811– collab expansion co-developm of IMC-C103C with $100m upfront/near-term with Genentech 2018-11-19
Noxxon–SEVERAL: investment, 201811 capital increase €6.21m incl €4.4m from Acuitas Capital LLC 2018-11-16
Boehringer–Epizyme: small-molecule cancer drugs, 201811– collab strategic ww to develop inhibitors toward two epigenetic targets 2018-11-15
Cadent Therapeutics–Access Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Access Industries 2018-11-15
Cadent Therapeutics–Atlas Venture: investment, 201811 financing round Series B totalling $40m incl co-lead investor Atlas Venture 2018-11-15
Cadent Therapeutics–Clal Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Clal Biotechnology Industries 2018-11-15
Cadent Therapeutics–Cowen: investment, 201811 financing round Series B totalling $40m incl co-lead investor Cowen Healthcare Investments 2018-11-15
Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research 2018-11-15
Cadent Therapeutics–Qiming: investment, 201811 financing round Series B totalling $40m incl co-investor Qiming Venture Partners 2018-11-15
Cadent Therapeutics–SEVERAL: investment, 201811 financing round Series B $40m co-led by Cowen Healthcare Investments + Atlas Venture 2018-11-15
I-Mab–MorphoSys: antibody cancer drug, 201811– license excl Greater China + KR for MOR210 with $3.5m upfront + $101.5m milestones + royalties 2018-11-15
Alicona–Bruker Corp: investment, 201811–201812 acquisition €na of Alicona Imaging GmbH by Bruker 2018-11-14
Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic 2018-11-14
Roivant–SEVERAL: investment, 201811 financing round $200m led by new investors NovaQuest Capital Management + RTW Investments 2018-11-13
Aimmune Therapeutics–Nestlé: investment, 201811 equity investment $98m w 3.24m shares at $30.27/share by Nestlé Health Science brings stake to 19% 2018-11-12
Amal Therapeutics–SEVERAL: investment, 201811 financing round Series B 2nd + final closing €21.2m co-led by BIVF + BioMedPartners + Helsinn 2018-11-12
CRISPR Therapeutics–MaxCyte: gene transfer technology, 201811– license commercial to use Flow Electroporation techn for CRISPR-based I-O therapies 2018-11-09
BioNTech–Univ Pennsylvania: mRNA technology, 201811– strategic research collab €na to develop mRNA vaccines for infectious disease 2018-11-05
Marinomed–SEVERAL: investment, 201811–201901 IPO €19.5m+€2.925m with 260k+39k new bearer shares at €75/share 2018-11-05
Curetis–SEVERAL: investment, 201811 private placement €8.9m net €7.3m with 4.45m new ordinary shaes at €2/share to institutional investors 2018-11-02
Omeicos–Forbion: investment, 201811 financing round Series C totalling €17m incl new + lead investor Forbion 2018-11-02
Omeicos–SEVERAL: investment, 201811 financing round Series C €17m led by new investor Forbion 2018-11-02
HBM–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D round 2018-11-01
Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins 2018-11-01
Wellington Partners–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D 2018-11-01
Grünenthal–AstraZeneca: esomeprazole, 201810– acquisition $922m of European rights to Nexium + ww ex US+JP rights to Vimovo 2018-10-30
Noscendo–SEVERAL: investment, 201810 financing round €7-digit led by Wieland Capital + incl HTGF + three business angels 2018-10-29
Symphogen–Thermo Fisher: mass spectrometer, 201810 supply Q Exactive Plus Orbitrap LC-MS/MS with BioPharma Option for biopharma QC 2018-10-29
Themis Bioscience–SEVERAL: investment, 201810– IPO €35m to €55.3m on Euronext Amsterdam POSTPONED 11/18 2018-10-29
Thermo Fisher–Symphogen: mass spectrometry, 201810– collab developm biopharma QC workflows using Q Exactive Plus Orbitrap LC-MS/MS system 2018-10-29
Galecto Biotech–BPCE: investment, 201810 financing round Series C totalling €79m incl new + co-investor Seventure Partners 2018-10-26
Galecto Biotech–OrbiMed: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor OrbiMed 2018-10-26
Galecto Biotech–SEVERAL: investment, 201810 financing round Series C €79m co-led by Ysios Capital + OrbiMed 2018-10-26
Galecto Biotech–Ysios Capital: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor Ysios Capital 2018-10-26
BASF–MIT: CRISPR technology, 201810– license ww non-excl to CRISPR-Cpf1 technology from Broad Institute for agriculture + industrial microbiology 2018-10-24
Novartis–Philips: digital health, 201810– collab developm of SMART Suite by Alcon for cataract surgery on HealthSuite digital platform 2018-10-23
Genome Biologics (DE)–EU (govt): grant, 201810 Horizon 2020 Phase 2 Grant €2.42m 2018-10-22
VTU–KonValue: investment, 201810 acquisition of VTU Technology by KonValue Group from VTU Holding GmbH + renaming as Validogen GmbH 2018-10-22
Endocyte–Novartis: investment, 201810– acquisition $2.1b in cash of Endocyte by Novartis ANNOUNCED 2018-10-18
JSR Corp–Berkeley Lights: cell line development, 201810– collab integrating SUREtechnology of Selexis with Beacon platform of BLI 2018-10-18
Oncgnostics–Thuringia (govt): investment, 201810 additional investment of €750k from bm|t + private investors 2018-10-17
Genedata–AstraZeneca: bioinformatics, 2018 collab existent development of Genedata Imagence s/w for HCS image analysis 2018-10-16
Quantum Analytics–Bruker Corp: analytical instruments, 201810– distribution of S2 Puma + S2 Polar + D2 Phaser analysers in the US by Quantum Analytics 2018-10-16
Warp Drive Bio–Revolution Medicines: investment, 201810 acquisition of Warp Drive Bio by Revolution Medicines 2018-10-16
LaVision BioTec–Miltenyi Biotec: investment, 201810 acquisition of LaVision BioTec GmbH by Miltenyi 2018-10-12
Gotham Therapeutics–Alexandria Real Estate: investment, 201810 financing round Series A totalling $54m incl co-investor Alexandria Venture Investments 2018-10-10
Gotham Therapeutics–Celgene: investment, 201810 financing round Series A totalling $54m incl co-investor Celgene Corp 2018-10-10
Gotham Therapeutics–Forbion: investment, 201810 financing round Series A totalling $54m incl $15m from co-lead investor Forbion IV Fund 2018-10-10
Gotham Therapeutics–GSK: investment, 201810 financing round Series A totalling $54m incl co-lead investor SR One 2018-10-10
Gotham Therapeutics–MacDougall Biomedical Communications: public relations, 201810 service existent by MacDougall 2018-10-10
Gotham Therapeutics–SEVERAL: investment, 201810 financing round Series A $54m co-led by Versant Ventures + Forbion + SR One 2018-10-10
Gotham Therapeutics–Versant Ventures: investment, 201810 financing round Series A totalling $54m incl founding + co-lead investor Versant Ventures 2018-10-10
SmartDyeLivery–PERSON: investment, 201810 financing round from bm|t + business angel from Munich 2018-10-10
SmartDyeLivery–SEVERAL: investment, 201810 financing round from bm|t + business angel from Munich 2018-10-10
SmartDyeLivery–Thuringia (govt): investment, 201810 financing round from bm|t + business angel from Munich 2018-10-10
DSM–Lipotype: mass spectrometry services, 201810 collab supply of shotgun skin lipidomics services by Lipotype to Royal DSM 2018-10-08
Lipoid–Lipotype: mass spectrometry services, 201810 collab supply of shotgun skin lipidomics services by Lipotype to Lipoid GmbH 2018-10-08
Sphingotec–HBM: investment, 201810 financing round totalling €20m incl co-lead investor HBM 2018-10-08
Sphingotec–SEVERAL: investment, 201810 financing round €20m co-led by HBM + Wellington Partners 2018-10-08
Sphingotec–Wellington Partners: investment, 201810 financing round totalling €20m incl co-lead investor Wellington Partners 2018-10-08
Axcelead–ERS Genomics: CRISPR technology, 201810– license non-excl ww to CRISPR/Cas9 genome editing IP of ERS Genomics Ltd 2018-10-04
GenAhead Bio–ERS Genomics: CRISPR technology, 201810– license non-excl to CRISPR/Cas9 genome editing IP of ERS Genomics Ltd 2018-10-04
Sanofi–Evotec: drug discovery, 201810– collab partnership BRIDGE LAB031 for early-stage projects out of academic research 2018-10-04
Curetis–Yorkville Group: credit, 201810– up to €20m convertible notes with attached warrants to YA II PN Ltd 2018-10-02
Oncgnostics–Biotech Alliances International: business services, 201810– supply service support for global partnering + distribution strategy 2018-10-02
Roche–GO Therapeutics: antibody cancer drug, 201810– license ww excl $9m upfront/near-term +$186m milestones + royalties for bispecific antibody 2018-10-02
next pagenext page 1 2 3 4 5 ... 54 55 56  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top